Epanova NDA accepted, but market may be swim against the tide
This article was originally published in Scrip
With the US FDA's acceptance of AstraZeneca's new drug application (NDA) for Epanova, a coated soft gelatin capsule containing a complex mixture of polyunsaturated free fatty acids derived from fish oils under investigationas a treatment for severe hypertriglyceridaemia – triglyceride levels greater than or equal to 500mg/dL – the UK drug maker has taken another step closer to bolstering its cardiovascular franchise.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.